Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Inovio Pharmaceuticals, Inc. - Common Stock
(NQ:
INO
)
1.515
+0.005 (+0.33%)
Streaming Delayed Price
Updated: 10:28 AM EST, Jan 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inovio Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Inovio Pharmaceuticals: Return On Capital Employed Insights
↗
June 24, 2021
During Q1, Inovio Pharmaceuticals's (NASDAQ:INO) reported sales totaled $371.12 thousand. Despite a 79.13% in earnings, the company posted a loss of $52.55 million. In Q4, Inovio...
Via
Benzinga
Inovio Pharmaceuticals Could See a Boost from Covid-19 Partnerships
↗
June 21, 2021
Some say INO stock could be the target of a short squeeze, but Inovio's Covid-19 vaccine program should be a sufficient reason to invest.
Via
InvestorPlace
Should You Buy Biotech ETFs Now?
↗
June 16, 2021
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
June 10, 2021
Gainers NuCana (NASDAQ:NCNA) shares moved upwards by 16.17% to $3.16 during Thursday's regular session. NuCana's stock is trading at a volume of 4.7 million shares...
Via
Benzinga
Why Inovio Stock Is Sinking Today
↗
June 10, 2021
Investors appear to be taking some profits after yesterday's huge gain.
Via
The Motley Fool
62 Biggest Movers From Yesterday
↗
June 10, 2021
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID...
Via
Benzinga
Twitter And Regeneron Lead The SPY In Another Mixed Day Of Trading
↗
June 09, 2021
U.S. indices at a mixed day of trading Wednesday as investors and traders weighed the U.S. 30-Year Treasury note falling to 2.1483%,...
Via
Benzinga
Why Inovio Stock Looks Ready To Break Out, Make Bullish Reversal
↗
June 09, 2021
Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares were trading higher Wednesday as retail traders continue to push high short interest stocks higher. The stock saw above average...
Via
Benzinga
INO Stock: 2 Big Reasons Inovio Pharmaceuticals Is Shooting Higher Today
↗
June 09, 2021
Today, INO stock is soaring amid a recently announced expanded partnership for its Covid-19 vaccine and potential short squeeze implications.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
June 09, 2021
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 347.96% to $9.9 during Wednesday's regular session. As of 12:30 EST, Aethlon Medical's stock is...
Via
Benzinga
Inovio Pharmaceuticals Insights: Return On Capital Employed
↗
June 08, 2021
During Q1, Inovio Pharmaceuticals's (NASDAQ:INO) reported sales totaled $371.12 thousand. Despite a 79.13% in earnings, the company posted a loss of $52.55 million. In Q4, Inovio...
Via
Benzinga
Inovio, Advaccine to Share $100M in Cost for Late-Stage COVID-19 Vaccine Trial
↗
June 08, 2021
Inovio Pharmaceuticals Inc (NASDAQ: INO) has expanded its partnership with Advaccine Biopharmaceuticals Suzhou Co Ltd to jointly conduct a global...
Via
Benzinga
48 Stocks Moving In Wednesday's Mid-Day Session
↗
June 09, 2021
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares jumped 371% to $10.41 in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An...
Via
Benzinga
These Vaccine Latecomers Could Still Win Big. Here's How
↗
June 07, 2021
The key is standing out from the crowd.
Via
The Motley Fool
Topics
Cannabis
Why Inovio Pharmaceuticals Stock Perked Up in May
↗
June 06, 2021
The biotech's pan-COVID-19 vaccine caught the eye of investors last month.
Via
The Motley Fool
I Would Hope Inovio Isn’t Attracting ANY Serious Money
↗
June 03, 2021
It seems as though INO stock will have a tough time getting and staying in double digits
Via
InvestorPlace
Is It Too Late to Buy Inovio Pharmaceuticals Stock?
↗
June 03, 2021
This troubled coronavirus vaccine developer has created far more woes than joys for investors.
Via
The Motley Fool
Step Aside AMC: Here Are The Most Shorted Stocks Right Now
↗
June 02, 2021
Just like in late January the common theme here is that all these stocks are extremely heavily shorted, and retail investors are seeking to squeeze the shorts once again and this time with even more...
Via
Talk Markets
Ocugen vs. Inovio: Where Is the Smart Money Going?
↗
May 23, 2021
They're both seeking share in the vaccine market.
Via
The Motley Fool
Inovio's Latest COVID Vaccine Results: Too Little, Too Late?
↗
May 21, 2021
Maybe not -- especially outside of the U.S.
Via
The Motley Fool
2 Things That May Boost This Beaten-Down Vaccine Stock
↗
May 20, 2021
This company could benefit from a near-term need -- and a long-term one, as well.
Via
The Motley Fool
High Flyers At Much Lower Altitudes
↗
May 14, 2021
Stocks with extreme valuations have taken a serious haircut since the space peaked on February 22nd.
Via
Talk Markets
1 Coronavirus Vaccine Company to Avoid Like The Plague in May (and Beyond)
↗
May 13, 2021
This biotech's prospects look dim.
Via
The Motley Fool
Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants, Animal Study Shows
↗
May 12, 2021
Inovio Pharmaceuticals Inc (NASDAQ: INO) has announced results from a preclinical study of its next-generation Pan-COVID-19 vaccine candidate, INO-4802, that...
Via
Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
↗
May 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
May 11, 2021
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW...
Via
Benzinga
Novavax, Inovio Stocks Hammered As Covid Vaccine News Disappoints
↗
May 11, 2021
Vaccine stocks crumbled Tuesday after Novavax announced a delay and Inovio's Covid vaccine disappointed in testing. Both NVAX stock and INO stock plunged.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 11, 2021
Gainers Cerecor (NASDAQ:CERC) shares rose 14.56% to $2.91 during Tuesday's pre-market session. The company's market cap stands at $281.4 million. Larimar...
Via
Benzinga
Inovio Pharmaceuticals (INO) Q1 2021 Earnings Call Transcript
↗
May 11, 2021
INO earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
↗
May 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.